Skip to main content

AnaptysBio, Inc. (ANAB)

NASDAQ: ANAB · IEX Real-Time Price · USD
28.55 0.02 (0.07%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap768.82M
Revenue (ttm)101.27M
Net Income (ttm)-8.71M
Shares Out27.39M
EPS (ttm)-0.32
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume94,819
Open28.41
Previous Close28.53
Day's Range27.71 - 28.65
52-Week Range17.72 - 35.85
Beta0.05
AnalystsBuy
Price Target35.33 (+23.7%)
Est. Earnings DateNov 4, 2021

About ANAB

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable t...

IndustryBiotechnology
IPO DateJan 26, 2017
CEOHamza Suria
Employees94
Stock ExchangeNASDAQ
Ticker SymbolANAB
Full Company Profile

Financial Performance

In 2020, AnaptysBio's revenue was $75.00 million, an increase of 837.50% compared to the previous year's $8.00 million. Losses were -$19.93 million, -79.52% less than in 2019.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for AnaptysBio stock is "Buy." The 12-month stock price forecast is 35.33, which is an increase of 23.75% from the latest price.

Price Target
$35.33
(23.75% upside)
Analyst Consensus: Buy

News

AnaptysBio Reveals Updated Imsidolimab Data In Severe Form Of Psoriasis

AnaptysBio Inc (NASDAQ: ANAB) has announced updated data from the GALLOP Phase 2 trial of imsidolimab in generalized pustular psoriasis (GPP). GPP is a rare and extreme form of psoriasis characterized b...

2 weeks ago - Benzinga

AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis

SAN DIEGO, Oct. 02, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune cont...

2 weeks ago - GlobeNewsWire

AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune con...

1 month ago - GlobeNewsWire

AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor Indication

The FDA has approved a second indication for GlaxoSmithKline plc's (NYSE: GSK) Jemperli (dostarlimab-gxly). The approval comes for adult patients with mismatch repair deficient (dMMR) recurrent or advan...

2 months ago - Benzinga

FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

SAN DIEGO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune cont...

2 months ago - GlobeNewsWire

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 86.67% and 8.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates

SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune cont...

2 months ago - GlobeNewsWire

AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference

SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune contr...

4 months ago - GlobeNewsWire

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 7.04% and -1.45%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates

SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune contr...

5 months ago - GlobeNewsWire

Earnings Preview: AnaptysBio, Inc. (ANAB) Q1 Earnings Expected to Decline

AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced d...

SAN DIEGO, April 23, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune con...

5 months ago - GlobeNewsWire

FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer

SAN DIEGO, April 22, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune con...

6 months ago - GlobeNewsWire

AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune con...

6 months ago - GlobeNewsWire

Why AnaptysBio Stock Is Attractive After 30% Selloff

AnaptysBio Inc's (NASDAQ: ANAB) stock seems attractive after the POPLAR data and the 30% selloff, while there are several catalysts over the next 12-18 months, according to Truist Securities. AnaptysBio...

7 months ago - Benzinga

Why AnaptysBio Stock Is Popping Today

This analyst is excited about the company's prospects.

7 months ago - The Motley Fool

Why AnaptysBio Shares Rose Nearly 14% on Thursday

A phoenix may well rise from the ashes of a disappointing clinical trial.

7 months ago - The Motley Fool

AnaptysBio (ANAB) Plunges on Lead Candidate Study Failure

AnaptysBio's (ANAB) lead pipeline candidate, imsidolimab, fails to meet primary endpoint of a mid-stage study evaluating it in patients with auto-inflammatory disease, palmoplantar pustulosis.

7 months ago - Zacks Investment Research

Why AnaptysBio Plummeted Today

The company's leading drug candidate failed to meet its primary endpoint in a phase 2 clinical trial.

7 months ago - The Motley Fool

AnaptysBio's Imsidolimab Fails To Separate From Placebo In Skin Blistering Disorder Study

AnaptysBio Inc (NASDAQ: ANAB) reports disappointing top-line data from its Phase 2 (POPLAR) trial of imsidolimab for palmoplantar pustulosis (PPP). The study failed to meet its primary endpoint of impro...

7 months ago - Benzinga

Why AnaptysBio Was a Stock Market Star on Friday

There was some encouraging news from across the Atlantic.

7 months ago - The Motley Fool

Why AnaptysBio Fell by as Much as 10% Today

Perhaps no news is bad news for the ambitious biotech.

7 months ago - The Motley Fool

AnaptysBio, Inc. (ANAB) Earnings Expected to Grow: Should You Buy?

AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

Why AnaptysBio Trounced the Market on Thursday

The biotech got a sharp upward shift in recommendation and target price from a prominent analyst.

8 months ago - The Motley Fool

Why ESSA Pharma, AnaptysBio And More Are Moving Today

ESSA Pharma Inc. (NASDAQ: EPIX) shares are trading higher after the company reported first-quarter earnings results and highlighted the presentation of Phase 1 pharmacology data of EPI-7386 for advanced...

Other symbols:EPIXPACB
8 months ago - Benzinga